Biohaven is a pre-revenue clinical-stage biotech with a broad late-stage pipeline, but its aggressive R&D investment has produced persistent quarterly net losses averaging over $150M and a deteriorating balance sheet. The company's equity has collapsed from $4...
Price trend, volume and key moving averages
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 10, 2026 | -$0.91-19.6% vs -$0.76 | — vs $490,492 |
Q2 2026 May 4, 2026 | -$0.88-2.3% vs -$0.86 | — vs $267,436 |
Q2 2026 Mar 2, 2026 | -$1.21+0.8% vs -$1.22 | — vs $400,000 |
Q4 2025 Nov 10, 2025 | -$1.64+14.1% vs -$1.91 | — vs $375,091 |
Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORT
Oral presentation selected: Phase 1 findings from the ongoing BHV1530-101 study will be featured in an oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), a leading international forum for early-phase oncology drug development. First-in-class FGFR3 ADC: BHV-1530 is a first-in-class potential FGFR3-directed antibody-drug conjugate incorporating Biohaven's proprietary TopoIx payload, that has shown early clinical activity with a differentiated and tolerable safety profile.
Biohaven says regulators placed a partial hold on a clinical study for its epilepsy drug candidate, opakalim. One rival drugmaker stands to benefit.
Biohaven Ltd. (NYSE:BHVN) on Thursday announced a partial clinical hold issued by the U.S. Food and Drug Administration (FDA) on new patient enrollment for its BHV-7000 program, while maintaining timelines for its lead pivotal study in refractory focal epilepsy.
Benchmark BHVN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Biohaven Ltd. (BHVN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $12.87 | $1.94B | -1.88 | — | — | -310.75% | — | |
| $43.58 | $1.44B | -4.48 | -43.89% | -287.84% | -37.99% | — | |
| $140.06 | $9.01B | -68.32 | -89.41% | 29.4% | 12.03% | — | |
| $0.39 | $7.45M | -0.12 | — | — | -187.45% | — | |
| $19.95 | $3.42B | 8.71 | 11.87% | 33.42% | 32.39% | — | |
| $20.50 | $1.51B | 6.21 | 18.52% | 80.56% | 30.03% | — |
Biohaven Ltd. (BHVN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Biohaven Ltd. (BHVN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 10, 2026·SEC
Aug 7, 2026·SEC
Jul 9, 2026·SEC
Get notified when BHVN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Biohaven Ltd. (BHVN) stock FAQ — growth, dividends, profitability & financials explained
Biohaven Ltd. (BHVN) reported a net loss of $586.8M for fiscal year 2025.
Biohaven Ltd. (BHVN) has a return on equity (ROE) of -310.8%. Negative ROE indicates the company is unprofitable.
Biohaven Ltd. (BHVN) had negative free cash flow of $511.9M in fiscal year 2025, likely due to heavy capital investments.
